EN

Your shopping cart

Amount

Total (VAT incl.)

VAT (21%)
Total
You have not added any reports to the cart yet.
Request reports
If you prefer to place your order via e-mail
contact us at: digital@azierta.com

Events and news

Blog
Home > Blog > Regulatory Affairs

Accessing the European Pharma Market: becoming a MAH through dossier adaptation (II)

The European pharma market is becoming more competitive and accessible through its effort to adopt globally acknowledged standards and requirements, it is not surprising the increasing interest of investors to this appealing market.

When a non-European company is considering investing in EU business opportunities different strategies may be implemented depending on the company needs. One of these possible strategies is becoming a MAH through dossier adaptation.

This option is recommended for Non-EU companies looking to adapt their own dossiers in order to be able to commercialise their own products in Europe through the adaptation of their manufacturing processes and facilities.

The dossier or multiple dossier must comply with European requirements and a bioequivalence study must be presented along with all the adapted documentation. An inspection must be carried out and once approved the company will be granted of a European MAH status. Once the company becomes a MAH is allowed to market their registered products along the European Union.

Deep local knowledge is crucial when a company is considering accessing this market to ensure a cost-effectiveness strategy and minimize time landing in EU.

At Azierta, we provide global support for accessing the European Pharma Market to Non-European companies. We are experts in Regulatory Affairs, Compliance and EU Requirements Related Services. For further information, please visit our website European Market Access Support Services, do not hesitate to contact us in case of any doubt.

Back

Related posts

How to proceed with an active ingredient that can be effective...

Although numerous clinical trials are underway, there is currently no evidence from controlled clinical trials to recommend...

Read more

Accessing the European Pharma Market: becoming a MAH through...

Positioned as the second largest pharmaceutical market in the world and showing a steady and extensive growth pattern, Europe’s...

Read more

Leading innovation in pharma & health

100 professionals

Over 100 professionals

500 clients

Over 500 clients

9 year experience

9 years of experience

Innovation

Leading innovation

Client oriented

100% client oriented

We are at your complete disposal for any inquiry

Thank you for getting in touch! We will contact you as soon as possible to help you out
There has been an error while submitting your form, please try again, or call us at 912 77 10 76
Schedule appointment

Schedule a video call with our field experts

schedule
We use "cookies" to improve your experience on our site. Cookies enable us to tailor messages and display ads to your interests. They also help us understand how our site is being used. By continuing to use our site you consent to use our cookies.